Jenscare Reports Strong Interim Results for First Half of 2025 with Significant Product Advancements

Jenscare's 2025H1 Interim Results Overview

Beijing, August 31, 2025 — Jenscare Scientific Co., Ltd. (HKEX: 9877), a pioneering firm in medical devices focusing on interventional treatment for structural heart diseases, has released its interim results for the first half of 2025, illustrating significant advancements in its products and a noteworthy financial trajectory.

Key Business Highlights

LuX-Valve Series and TTVR System

Jenscare has marked significant progress with its LuX-Valve series, particularly in China, where a multicenter clinical trial for approval by the NMPA has transitioned into the long-term follow-up phase, showcasing excellent outcomes. Furthermore, the randomized controlled trial for optimized medical therapy has successfully completed its subject enrollment. The application for registration has been officially accepted by the NMPA.

In Europe, the LuX-Valve Plus has wrapped up the six-month follow-up for the TRINITY study, a clinical trial aimed at acquiring the much-coveted CE Marking. The device is currently under review for registration.

In the United States, the IDE Early Feasibility Study for LuX-Valve Plus has concluded subject enrollment, and the company successfully obtained reimbursement for the device and associated costs from the CMS. Jenscare is vigorously working on advancing its timeline to receive approval for a pivotal study.

Ken-Valve and TAVR System

Jenscare’s Ken-Valve, which had been approved by NMPA, has swiftly penetrated the market. The company is fostering commercialization initiatives, seeing smooth transitions in hospital adoption rates for this system designed to address aortic regurgitation.

JensClip and TMVr System

As Jenscare expands its portfolio, a registration application for the JensClip has been submitted to the NMPA, moving into the registration phase. Internationally, the company is pushing forward with its globalization strategy; pre-commercialization implantations have been conducted overseas, yielding admirable results. Activities aimed at securing CE Marking are also in progress.

Financial Performance Highlights

Jenscare reported total revenue of $3.6 million, with gross profit standing at $1.7 million, and a sales profit of $1.1 million. The gross profit margin is nearly 90%, reflecting strong sales efficiency, while the sales profit margin remains close to 60%.

However, the adjusted non-IFRS loss amounted to $12.9 million, indicating a slight decrease of approximately 3% compared to the first half of 2024. Each ordinary shareholder faced a net loss per share of $0.06. On a positive note, the company has reported cash and cash equivalents, along with term deposits and other financial assets, totaling $84.6 million. Notably, the net cash expenditure for operating activities has lowered by around 15% from the previous year, sitting at $13 million.

Conclusion

In summation, Jenscare is poised for notable growth within the medical device sector. As it continues to innovate and address critical clinical needs with its product range, the company shows promise not just in enhancing healthcare provision for heart disease patients but also in maintaining a robust financial health. The future looks bright for Jenscare as it navigates through upcoming regulatory challenges and market opportunities.